Last 19 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 17.69 | 1.37 | 1.82 | 3.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.06 | 2.89 | 1.82 | 4.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.4% | 83.9% | 79.4% | 90.7% | 91.1% | 98.2% | 84.4% | 87.3% | 89.5% | 89.5% | 95.1% | 80.0% | 84.2% | 84.2% | 85.6% | 85.6% | 100.0% | -21.4% | 104.6% | -0.6% |
| — | -14.5% | -5.8% | +4.0% | +1.7% | +9.7% | -11.2% | +9.1% | +6.3% | +6.3% | +11.1% | -6.5% | -15.8% | +493.6% | -18.2% | +14856.4% | — | — | — | — | |
| Operating Margin | -211.1% | -248.9% | -191.8% | -237.1% | -361.2% | 22.8% | -671.1% | -238.7% | -405.2% | -405.2% | -2910.1% | -3354.6% | -5332.9% | -5332.9% | -4014.9% | -4014.9% | -6620.5% | -424.2% | -2118.0% | -898.0% |
| — | -1190.7% | +71.4% | +0.7% | +10.9% | +105.6% | +76.9% | +92.9% | +92.4% | +92.4% | +27.5% | +16.4% | +19.4% | -1157.2% | -89.6% | -347.1% | — | — | — | — | |
| Net Margin | -216.5% | -270.2% | -191.5% | -252.8% | -362.3% | 19.8% | -660.0% | -282.0% | -421.0% | -421.0% | -2617.7% | -3017.4% | -5442.6% | -5442.6% | -10202.7% | -10202.7% | -6719.5% | -118.4% | -1899.5% | -1286.1% |
| — | -1465.7% | +71.0% | +10.3% | +14.0% | +104.7% | +74.8% | +90.7% | +92.3% | +92.3% | +74.3% | +70.4% | +19.0% | -4497.6% | -437.1% | -693.3% | — | — | — | — |
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -150.2% | -85.0% | -63.6% | -124.4% | -108.2% | 38.5% | -156.0% | -79.8% | -68.7% | -41.8% | -29.1% | -34.1% | -46.4% | -45.1% | -83.1% | — | — | — | — | — |
| — | -320.8% | +59.2% | -55.9% | -57.6% | +192.0% | -435.3% | -134.1% | -47.9% | +7.3% | +64.9% | — | — | — | — | — | — | — | — | — | |
| ROA | -36.7% | -22.4% | -18.3% | -20.9% | -19.9% | 5.8% | -19.3% | -14.0% | -15.1% | -14.8% | -14.6% | -18.9% | -23.9% | -29.3% | -65.0% | -64.3% | -38.1% | -0.3% | -19.7% | -0.6% |
| — | -485.5% | +5.5% | -49.0% | -31.9% | +139.3% | -32.0% | +25.9% | +37.0% | +49.6% | +77.5% | +70.6% | +37.3% | -8322.2% | -230.6% | -10576.9% | — | — | — | — | |
| ROIC | -114.1% | -69.3% | -61.0% | -57.8% | -40.8% | 13.0% | -53.5% | -36.0% | -43.5% | -47.2% | -40.1% | -47.6% | -60.3% | -85.4% | -192.7% | — | — | — | — | — |
| — | -634.4% | -14.1% | -60.8% | +6.1% | +127.5% | -33.4% | +24.4% | +27.8% | +44.8% | +79.2% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.48 | 3.70 | 1.48 | 2.54 | 6.09 | 2.19 | 25.42 | 2.79 | 4.39 | 1.78 | 0.88 | 0.46 | 0.63 | 0.47 | 0.11 | — | — | — | — | — |
| — | +69.1% | -94.2% | -9.1% | +38.7% | +23.0% | +2794.9% | +506.7% | +601.2% | +278.4% | +671.1% | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | 7.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.79 | 1.22 | 1.79 | 1.54 | 1.26 | 1.84 | 1.44 | 2.74 | 1.86 | 3.05 | 5.22 | 8.25 | 3.91 | 4.94 | 4.50 | 4.73 | 9.41 | 2.59 | 5.21 | 5.59 |
| — | -33.9% | +24.5% | -43.8% | -32.0% | -39.5% | -72.4% | -66.8% | -52.5% | -38.3% | +16.0% | +74.2% | -58.5% | +90.9% | -13.7% | -15.3% | — | — | — | — | |
| Quick Ratio | 1.77 | 1.18 | 1.77 | 1.53 | 1.26 | 1.83 | 1.42 | 2.73 | 1.85 | 3.04 | 5.21 | 8.25 | 3.91 | 4.94 | 4.50 | 4.73 | 9.41 | 2.59 | 5.21 | 5.59 |
| — | -35.4% | +24.8% | -43.9% | -31.9% | -39.7% | -72.7% | -66.9% | -52.7% | -38.5% | +15.8% | +74.2% | -58.5% | +90.9% | -13.7% | -15.3% | — | — | — | — | |
| Interest Coverage | -22.42 | -28.05 | -24.85 | — | — | 6.70 | -26.24 | -4.02 | -15.81 | -15.81 | -48.74 | -48.74 | -106.99 | -106.99 | -345.82 | -345.82 | -6.12 | 0.13 | -1.08 | -0.82 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 19 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AAPG stock.
Ascentage Pharma Group International's current P/E is -7.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ascentage Pharma Group International's current operating margin is -211.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ascentage Pharma Group International's business trajectory between earnings reports.